866-997-4948(US-Canada Toll Free)

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 187 Pages

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016, provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Overview 11
Therapeutics Development 12
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Stage of Development 12
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Therapy Area 13
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Indication 14
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Products Glance 17
Late Stage Products 17
Early Stage Products 18
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Companies 19
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Therapeutics Assessment 32
Assessment by Monotherapy/Combination Products 32
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39
Advenchen Laboratories, LLC 39
Amgen Inc. 40
ArQule, Inc. 41
Astellas Pharma Inc. 42
AstraZeneca Plc 43
Asubio Pharma Co., Ltd. 44
AVEO Pharmaceuticals, Inc. 45
Bayer AG 46
BioArctic AB 47
Boehringer Ingelheim GmbH 48
Bristol-Myers Squibb Company 49
CardioVascular BioTherapeutics, Inc. 50
Celon Pharma Sp. z o.o. 51
Debiopharm International SA 52
Eddingpharm 53
Eisai Co., Ltd. 54
Eli Lilly and Company 56
F. Hoffmann-La Roche Ltd. 57
Hutchison MediPharma Limited 58
Incyte Corporation 59
Johnson & Johnson 60
Les Laboratoires Servier SAS 61
Metacrine Inc 62
Novartis AG 63
OncoMax 64
Principia Biopharma Inc. 65
Teva Pharmaceutical Industries Ltd. 66
Vichem Chemie Research Ltd. 67
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Drug Profiles 68
Aea-25 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Aea-4 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
ARQ-087 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
ASP-5878 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
AZD-4547 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
BAY-1163877 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
BMS-986036 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
brivanib alaninate - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
CEP-11981 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
CPL-043 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
CVBT-141B - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
CVBT-141C - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
CVBT-141D - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
CVBT-141H - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Debio-1347 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Drugs to Agonize Fibroblast Growth Factor Receptor 1 for Type 2 Diabetes - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
E-7090 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
EDP-317 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
erdafitinib - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
FGF-1 Program - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
HMPL-012 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
HMPL-453 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
INCB-54828 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
infigratinib - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
lenvatinib mesylate - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
lucitanib - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
LY-2874455 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Monoclonal Antibody to Antagonize FGFR1 for Cancer - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
nintedanib - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
OMRCA-01 - Drug Profile 131
Product Description 131
Mechanism Of Action 131
R&D Progress 131
pazopanib hydrochloride - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
pazopanib hydrochloride + pembrolizumab - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
PRN-1371 - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 144
Product Description 144
Mechanism Of Action 144
R&D Progress 144
regorafenib - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
RG-7992 - Drug Profile 156
Product Description 156
Mechanism Of Action 156
R&D Progress 156
S-49076 - Drug Profile 157
Product Description 157
Mechanism Of Action 157
R&D Progress 157
SC-0806 - Drug Profile 159
Product Description 159
Mechanism Of Action 159
R&D Progress 159
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 160
Product Description 160
Mechanism Of Action 160
R&D Progress 160
SUN-11602 - Drug Profile 161
Product Description 161
Mechanism Of Action 161
R&D Progress 161
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Dormant Projects 162
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Discontinued Products 167
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Featured News & Press Releases 170
Nov 07, 2016: Bayer Submits Supplemental New Drug Application for Stivarga (regorafenib) for Advanced Liver Cancer 170
Nov 07, 2016: Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer 171
Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 172
Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 173
Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 174
Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 175
Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 176
Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 178
Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 178
Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 179
Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 180
Sep 28, 2016: Bayer to Showcase Regorafenib at ESMO 2016 Congress 181
Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 183
Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 183
Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 185
Appendix 186
Methodology 186
Coverage 186
Secondary Research 186
Primary Research 186
Expert Panel Validation 186
Contact Us 186
Disclaimer 187

List of Tables
Number of Products under Development for, H2 2016 12
Number of Products under Development by Therapy Area, H2 2016 13
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Development by Companies, H2 2016 (Contd..3) 24
Products under Development by Companies, H2 2016 (Contd..4) 25
Products under Development by Companies, H2 2016 (Contd..5) 26
Products under Development by Companies, H2 2016 (Contd..6) 27
Products under Development by Companies, H2 2016 (Contd..7) 28
Products under Development by Companies, H2 2016 (Contd..8) 29
Number of Products under Investigation by Universities/Institutes, H2 2016 30
Products under Investigation by Universities/Institutes, H2 2016 31
Assessment by Monotherapy/Combination Products, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Pipeline by Advenchen Laboratories, LLC, H2 2016 39
Pipeline by Amgen Inc., H2 2016 40
Pipeline by ArQule, Inc., H2 2016 41
Pipeline by Astellas Pharma Inc., H2 2016 42
Pipeline by AstraZeneca Plc, H2 2016 43
Pipeline by Asubio Pharma Co., Ltd., H2 2016 44
Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 45
Pipeline by Bayer AG, H2 2016 46
Pipeline by BioArctic AB, H2 2016 47
Pipeline by Boehringer Ingelheim GmbH, H2 2016 48
Pipeline by Bristol-Myers Squibb Company, H2 2016 49
Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016 50
Pipeline by Celon Pharma Sp. z o.o., H2 2016 51
Pipeline by Debiopharm International SA, H2 2016 52
Pipeline by Eddingpharm, H2 2016 53
Pipeline by Eisai Co., Ltd., H2 2016 54
Pipeline by Eli Lilly and Company, H2 2016 56
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 57
Pipeline by Hutchison MediPharma Limited, H2 2016 58
Pipeline by Incyte Corporation, H2 2016 59
Pipeline by Johnson & Johnson, H2 2016 60
Pipeline by Les Laboratoires Servier SAS, H2 2016 61
Pipeline by Metacrine Inc, H2 2016 62
Pipeline by Novartis AG, H2 2016 63
Pipeline by OncoMax, H2 2016 64
Pipeline by Principia Biopharma Inc., H2 2016 65
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 66
Pipeline by Vichem Chemie Research Ltd., H2 2016 67
Dormant Projects, H2 2016 162
Dormant Projects (Contd..1), H2 2016 163
Dormant Projects (Contd..2), H2 2016 164
Dormant Projects (Contd..3), H2 2016 165
Dormant Projects (Contd..4), H2 2016 166
Discontinued Products, H2 2016 167
Discontinued Products (Contd..1), H2 2016 168
Discontinued Products (Contd..2), H2 2016 169

List of Figures
Number of Products under Development for, H2 2016 12
Number of Products under Development by Therapy Area, H2 2016 13
Number of Products under Development by Top 10 Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 32
Number of Products by Mechanism of Actions, H2 2016 33
Number of Products by Stage and Mechanism of Actions, H2 2016 33
Number of Products by Routes of Administration, H2 2016 35
Number of Products by Stage and Routes of Administration, H2 2016 35
Number of Products by Molecule Types, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *